The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders;Das endogene cannabinoidsystem. Therapeutische implikationen der cannabinoide bei neurologisch-psychiatrischen erkrankungen

Nervenarzt

Volumn 76, Issue 9, 2005, Pages 1062-1076

  Schneider, U ^a   Seifert, J ^a   Karst, M ^a   Schlimme, J ^a   Cimander, K ^b   Muller Vahl K R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Praxis für Allgemeinmedizin Suchtmedizin   (Germany)

Author keywords

Cannabis; Endocannabinoid system; Therapy

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AJULEMIC ACID; ANANDAMIDE; ANTIEMETIC AGENT; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DEXANABINOL; DRONABINOL; PALMIDROL; RIMONABANT;

ALZHEIMER DISEASE; AMNESIA; APPETITE; BASAL GANGLION; BRAIN REGION; CEREBELLUM; CHEMOTHERAPY INDUCED EMESIS; COGNITIVE DEFECT; DELIRIUM; DEPERSONALIZATION; DYSTONIA; EPILEPSY; EUPHORIA; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; IMMUNE SYSTEM; IMMUNOMODULATION; MEMORY; MENTAL DISEASE; MIGRAINE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; PAIN; PANIC; PARKINSON DISEASE; PSYCHOSIS; REVIEW; SIDE EFFECT; WASTING SYNDROME;

ANIMALS; BRAIN; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; MENTAL DISORDERS; MODELS, BIOLOGICAL; NEUROMUSCULAR DISEASES;

EID: 24744471824     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-005-1888-7     Document Type: Review

References (100)

1. Ameri A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58:315-348
2. Ameri A, Wilhelm A, Simmet T (1999) Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Br J Pharmacol 126:1831-1839
3. Baker D, Pryce G, Croxford JL et al. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84-87
4. Baker D, Pryce G, Croxford JL et al. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300-302
5. Berding G, Muller-Vahl K, Schneider U et al. (2004) [(123)I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB(1) receptors before and after Delta(9)-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry 55:904-915
6. Breivogel CS, Griffin G, Di Marzo V et al. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163
7. Bruera E (1992) Clinical mangement of anorexia and chachexia in patients with advanced cancer. Oncology 49:35-42
8. Burstein SH (2000) Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr Pharm Des 6:1339-1345
9. Burstein SH, Karst M, Schneider U et al. (2004) Ajulemic acid: a novel cannabinoid produces analgesia without a "high". Life Sci 75:1513-1522
10. Bundeszentrale für gesundheitliche Aufklärung (BzgA) (2001) Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland. BzgA, Köln
11. Cabral GA, Toney DM, Fischer-Stenger K et al. (1995) Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 56:2065-2072
12. Cabral GA, Vasquez R (1991) Effects of marijuana on macrophage function. Adv Exp Med Biol 288:93-105
13. Campbell FA, Tramer MR, Carroll D et al. (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13-16
14. Chaytor A, Martin P, Evans W et al. (1999) The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520(Pt2):539-550
15. Christopoulos A, Coles P, Lay L et al. (2001) Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br J Pharmacol 132:1281-1291
16. Clifford DB (1983) Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 13:669-671
17. Consroe P, Benedito MA, Leite JR et al. (1982) Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 83:293-298
18. Consroe P, Laguna J, Allender J et al. (1991) Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40:701-708
19. Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30:277-282
20. Cota D, Marsicano G, Lutz B et al. (2003) Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 27:289-301
21. Cunha JM, Carlini EA, Pereira AE et al. (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175-185
22. Di Marzo V, Blumberg PM, Szallasi A (2002) Endovanilloid signaling in pain. Curr Opin Neurobiol 12:372-379
23. Di Marzo V, Melck D, Bisogno T et al. (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action.Trends Neurosci 21:521-528
24. Diener HC, Limmroth V (2001) Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 10:1831-1845
25. Einecke D (2004) [A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes]. MMW Fortschr Med 146:10-11
26. Elsohly MA, Dewit H, Wachtel SR et al. (2001) Delta9- tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 25:565-571
27. Fernandez-Ruiz J, Berrendero F, Hernandez ML et al. (2000) The endogenous cannabinoid system and brain development. Trends Neurosci 23:14-20
28. Fox SH, Kellett M, Moore AP et al. (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145-149
29. Frankel JP, Hughes A, Lees AJ et al. (1990) Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 53:436
30. Fride E (2002) Endocannabinoids in the central nervous system - an overview. Prostaglandins Leukot Essent Fatty Acids 66:221-233
31. Fukudome Y, Ohno-Shosaku T, Matsui M et al. (2004) Two distinct classes of muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1/M3-mediated indirect suppression through endocannabinoid signalling. Eur J Neurosci 19:2682-2692
32. Galiegue S, Mary S, Marchand J et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61
33. Giuffrida A, Piomelli D (2000) The endocannabinoid system: a physiological perspective on its role in psychomotor control. Chem Phys Lipids 108:151-158
34. Grotenhermen F (2004) Pharmacology of cannabinoids. Neuroendocrinol Lett 25:14-23
35. Grotenhermen F (2004) Hanf als Medizin. AT Verlag, Baden
36. Guimaraes F, Chiaretti T, Graeff F et al. (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100:558-559
37. Habayeb OM, Bell SC, Konje JC (2002) Endogenous cannabinoids: metabolism and their role in reproduction. Life Sci 70:1963-1977
38. Haller J, Varga B, Ledent C et al. (2004) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15:299-304
39. Hampson A, Grimaldi M, Axelrod J et al. (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268-8273
40. Hanus L, Abu-Lafi S, Fride E et al. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662-3665
41. Jabusch JC, Schneider U, Altenmueller E (2004) Delta-9- Tetrahydrocannabinol (THC) in treatment of muscian's dystonia. Mov Disord 19:990-991
42. Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178:116-122
43. Karst M, Salim K, Conrad I et al. (2003) Analgesic effects of synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 120:103-105
44. Kathuria S, Gaetani S, Fegley D et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81
45. Killestein J, Hoogervorst EL, Reif M et al. (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58:1404-1407
46. Klein TW, Lane B, Newton CA et al. (2000) The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225:1-8
47. Knoller N, Levi L, Shoshan I et al. (2002) Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med 30:548-554
48. Kraus L, Augustin R, Müller-Klathoff T (2001) Konsumtrends und Konsumverhalten. Hüllinghorst RNeuland, Geesthacht, S 119-132
49. Kreitzer AC, Regehr WG (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717-727
50. Lambert D, Vandevoorde S, Jonsson K et al. (2002) The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 9:663-674
51. Lange J, Kruse C (2004) Recent advances in CB1 cannabinoid receptor antagonists. Curr Opin Drug Discov Devel 7:498-506
52. Leker R, Gai N, Mechoulam R et al. (2003) Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 34:2000-2006
53. Lichtman AH, Dimen KR, Martin BR (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 119:282-290
54. Liu J, Li H, Burstein SH et al. (2003) Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 63:983-992
55. Lopez-Cepero M, Friedman M, Klein T et al. (1986) Tetrahydrocannabinol- induced suppression of macrophage spreading and phagocytic activity in vitro. J Leukoc Biol 39:679-686
56. Lyman WD, Sonett JR, Brosnan CF et al. (1989) Delta 9- tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23:73-81
57. Maccarrone M, Attina M, Cartoni A et al. (2001) Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem 76:594-601
58. Maccarrone M, Finazzi-Agro A (2002) Endocannabinoids and their actions. Vitam Horm 65:225-255
59. Massa F, Marsicano G, Hermann H et al. (2004) The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113:1202-1209
60. Mcallister S, Griffin G, Satin L et al. (1999) Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther 291:618-626
61. Mccoy KL, Matveyeva M, Carlisle SJ et al. (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther 289:1620-1625
62. Mechoulam R, Panikashvili D, Shohami E (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 8:58-61
63. Milton NG (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett 332:127-130
64. Moranta D, Esteban S, Garcia-Sevilla JA (2004) Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 369:516-524
65. Mueller-Vahl KR, Koblenz A, Jobges M et al. (2001) Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 34:19-24
66. Mueller-Vahl KR, Schneider U, Emrich HM (1999) Nabilone increases choreatic movements in Huntington's disease. Mov Disord 14:1038-1040
67. Mueller-Vahl KR, Schneider U, Koblenz A et al. (2002) Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57-61
68. Mueller-Vahl KR, Prevedel H, Theloe K et al. (2003) Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384-388
69. Mueller-Vahl KR, Schneider U, Prevedel H et al. (2003) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459-465
70. Naef M, Curatolo M, Petersen-Felix S et al. (2003) The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105:79-88
71. Neuhaus O, Kieseier B, Klimke A et al. (2004) Cannabinoids in multiple sclerosis Opportunity or threat?. Nervenarzt 75:1022-1026
72. Ohno-Shosaku T, Maejima T, Kano M (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29:729-738
73. Parolaro D, Massi P, Rubino T et al. (2002) Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 66:319-332
74. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180
75. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611
76. Petro DJ, Ellenberger CJ (1981) Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 21:413-416
77. Porter A, Sauer J, Knierman M et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020-1024
78. Ralevic V, Kendall DA, Randall MD et al. (2002) Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci 71:2577-2594
79. Rice AS, Farquhar-Smith WP, Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66:243-256
80. Russo E (1998) Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain 76:3-8
81. Sacerdote P, Massi P, Panerai AE et al. (2000) In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 109:155-163
82. Schlimme J, Rada D, Schneider U (2001) [Cannabis consumption and its psychosocial effects in a comparison of different cultures]. Fortschr Neurol Psychiatr 69:367-373
83. Schnelle M, Grotenhermen F, Reif M et al. (1999) Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forsch Komplementarmed 6 [Suppl 3]:28-36
84. Shakespeare D, Boggild M, Young C (2004) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 4:CD001332
85. Shen M, Piser TM, Seybold VS et al. (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322-4334
86. Sieradzan KA, Fox SH, Hill M et al. (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57:2108-2111
87. Strangman N, Walker J (1999) Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 82:472-477
88. Sugiura T, Kondo S, Kishimoto S et al. (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605-612
89. Tang JL, Lancz G, Specter S et al. (1992) Marijuana and immunity: tetrahydrocannabinol-mediated inhibition of growth and phagocytic activity of the murine macrophage cell line, P388D1. Int J Immunopharmacol 14:253-262
90. Ungerleider JT, Andyrsiak T, Fairbanks L et al. (1987) Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 7:39-50
91. Van Der Stelt M, Veldhuis WB, Maccarrone M et al. (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26:317-346
92. Vaney C, Heinzel-Gutenbrunner M, Jobin P et al. (2004) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10:417-424
93. Venance L, Piomelli D, Glowinski J et al. (1995) Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376:590-594
94. Volicer L, Stelly M, Morris J et al. (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 12:913-919
95. Wade D, Makela P, Robson P et al. (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10:434-441
96. Walker J, Hohmann A, Martin W et al. (1999) The neurobiology of cannabinoid analgesia. Life Sci 65:665-673
97. Werner N, Koch J (2003) Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res 967:290-292
98. Yoshihara S, Morimoto H, Yamada Y et al. (2004) Cannabinoid Receptor Agonists Inhibit Sensory Nerve Activation in Guinea Pig Airways. Am J Respir Crit Care Med 170:941-946
99. Zajicek J, Fox P, Sanders H et al. (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517-1526
100. Zhu LX, Sharma S, Stolina M et al. (2000) Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165:373-380